New Market - June 24, 2019
Novo Nordisk’s Esperoct approved in the EU
The European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents and adults with haemophilia A.
Clinical Trials - June 12, 2019
New clinical trials results from Novo Nordisk
Findings presented from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza (liraglutide 1.8 mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. Data from both trials were presented at the American Diabetes Association (ADA) […]
Pharma Business - May 7, 2019
Novo Nordisk’s operating profit increased by 14% in Q1 2019
The company’s sales increased by 9% in Danish kroner and by 4% at CER to DKK 29.3 billion. Operating profit growth of 8% at CER was positively impacted by a reversal of write-downs of oral semaglutide prelaunch inventory. In addition, sales in International Operations increased by 13% in Danish kroner (13 % at CER), driven […]
Collaboration - April 23, 2019
Novo Nordisk and Gilead Sciences initiate collaboration
The two companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also […]
Pharma Business - April 5, 2019
Novo Nordisk invests DKK 650 million in its Kalundborg site
The company will upgrade and expand facilities at its production site in Kalundborg, Denmark, currently manufacturing a range of products for diabetes treatment. The site will be rebuilt to allow for future production of the next generation of products. The projects are expected to be completed in 2020. “The investments in production facilities highlight Novo […]
Pharma Business - March 26, 2019
Novo Nordisk has submitted two new NDAs to the FDA
The company announced the submission of two New Drug Applications (NDAs) for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic (semaglutide). Seeking approval for an indication for the treatment of adults with type 2 diabetes An NDA was submitted for oral semaglutide […]
